PREVIOUS
✖
Phase III trial for COVAXIN
November 23 , 2020
1468 days
1030
0
- Bharat Biotech announced the start of the third phase of clinical trials for COVAXIN.
- It will be the largest clinical trial conducted for the vaccine of Coronavirus in India.
- It is also approved by the Drugs Controller General of India (DCGI).
- It will be conducted in partnership with ICMR (Indian Council of Medical Research).
- COVAXIN is India’s indigenous COVID-19 vaccine.
- It has been developed by Bharat Biotech in collaboration with the National Institute of Virology (NIV) and Indian Council of Medical Research (ICMR).
- It is developed and manufactured in the BSL-3 (Bio-Safety Level 3) biocontainment facility of Bharat Biotech.
- It is manufactured in a Vero cell manufacturing platform.
Leave a Reply
Your Comment is awaiting moderation.